NCT02156908

D-serine and Cognitive Remediation in Schizophrenia

D-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Nathan Kline Institute for Psychiatric Research · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

The investigators will test the effects of 3 days of D-serine (DSR) on auditory plasticity in a sensory based remediation (SBR) paradigm

Detailed description

We will enroll 8 subjects in an open label, three session pilot in patients will receive three sessions of tone matching SBR. 5 Subjects will receive D-serine (60mg/kg) taken 1x each week during the SBR sessions. Subjects will receive study drug 30 minutes prior to session. 3 subjects received no intervention

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	D-serine	D-serine 60 mg/kg

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2014-06-05
• Last updated: 2020-10-08
• Results posted: 2020-10-08

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study